New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal. The study is by Dr Hunter Thomas Hoffman, Eli Lilly and Company, Indianapolis, IN, USA – the sponsor of the study and manufacturer of orforglipron – and colleagues.
Obesity, a chronic progressive disease, is exacerbated by oestrogen deficiency during menopause. Orforglipron, an oral small-molecule, non-peptide GLP-1 receptor agonist, was associated with significant body weight (BW) reductions in ATTAIN-1 and -2 studies, one of which looked at people living with overweight or obesity but not diabetes (ATTAIN-1) and the other with both conditions (ATTAIN-2). This additional analysis evaluates orforglipron‘s effect on BW in women by menopausal stage.
Female participants with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related medical condition in ATTAIN-1 and -2 were analysed by menopausal status: pre-, peri-, or post-menopause, with the number of women in each category receiving orforglipron or placebo ranging from 142 to 225. BW, waist circumference (WC), waist-to-height ratio changes and the proportion achieving BW reduction thresholds (≥5%, ≥10%, ≥15%, ≥20%) vs placebo (PBO) were assessed at 72 weeks.
For women given orforglipron, significant and similar reductions in body weight up to 14% were experienced for pre-menopausal, peri-menopausal and post-menopausal women in ATTAIN-1, and in ATTAIN-2. (see results table full abstract)
Significant reductions in waist circumference of up to 12.5 cm were observed across subgroups with orforglipron for both studies. With orforglipron, up to 83% experienced at least 5% body weight reduction vs 30% with placebo. More orforglipron-treated participants experienced a shift to lower waist-to-height ratio categories than placebo.
All of the authors are employees of Eli Lilly, the manufacturer of orforglipron.